NCT05959109

A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants

A Phase 1, Single-Dose Study to Assess the Relative Bioavailability and Tolerability of Subcutaneous Peresolimab Test Formulations in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to look at the amount of the study drug, peresolimab, that gets into the blood stream and how long it takes the body to get rid of it when given under the skin using test formulations versus reference formulation in healthy participants. The study will also evaluate the safety and tolerability of peresolimab and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately up to 17 weeks, including screening.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Peresolimab	Administered SC

Timeline

• Start date: 2023-07-21
• Primary completion: 2024-01-11
• Completion: 2024-01-11
• First posted: 2023-07-25
• Last updated: 2024-01-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study